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Abstract
Introduction: Due to resource limitations, few critical care interventions have been rigorously evaluated with
adequately powered randomized clinical trials (RCTs). There is a need to improve the efficiency of RCTs in critical
care so that more definitive high quality RCTs can be completed with the available resources. The objective of this
study was to validate and demonstrate the utility of a novel composite outcome measure, persistent organ
dysfunction (POD) plus death, for clinical trials of critically ill patients.
Methods: We performed a secondary analysis of a dataset from a prospective randomized trial involving 38
intensive care units (ICUs) in Canada, Europe, and the United States. We define POD as the persistence of organ
dysfunction requiring supportive technologies during the convalescent phase of critical illness and it is present
when a patient has an ongoing requirement for vasopressors, dialysis, or mechanical ventilation at the outcome
assessments time points. In 600 patients enrolled in a randomized trial of nutrition therapy and followed
prospectively for six months, we evaluated the prevalence of POD and its association with outcome.
Results: At 28 days, 2.3% of patients had circulatory failure, 13.7% had renal failure, 8.7% had respiratory failure,
and 27.2% had died, for an overall prevalence of POD + death = 46.0%. Of survivors at Day 28, those with POD,
compared to those without POD, had a higher mortality rate in the six-month follow-up period, had longer ICU
and hospital stays, and a reduced quality of life at three months. Given these rates of POD + death and using a
two-sided Chi-squared test at alpha = 0.05, we would require 616 patients per arm to detect a 25% relative risk
reduction (RRR) in mortality, but only 286 per arm to detect the same RRR in POD + mortality.
Conclusions: POD + death may be a valid composite outcome measure and compared to mortality endpoints,
may reduce the sample size requirements of clinical trials of critically ill patients. Further validation in larger clinical
trials is required.
Introduction
In the critical care setting, randomized controlled trials
(RCTs) focusing on clinically important endpoints have
become the preferred source of evidence on which to
base clinical recommendations. However, due to resource
limitations, few critical care interventions have been rig-
orously evaluated with adequately powered RCTs. There
is a need to improve the efficiency of RCTs in critical
care so that more definitive high quality RCTs can be
completed with the available resources.
To judge the efficacy of new interventions or thera-
pies, clinicians and researchers consider the treatment
effect of the new intervention on clinically important
primary outcome(s). Historically, 28-day mortality has
been used as the primary endpoint for large scale trials
of critical care interventions. In the last decade, there
has been increasing awareness of other endpoints, such
as organ failure, infectious complications, and quality of
life and a movement beyond the 28-day window to
longer-term outcomes, such as hospital survival or six-
m o n t hq u a l i t yo fl i f e[ 1 , 2 ] .T h es a m p l es i z er e q u i r e dt o
demonstrate whether an intervention is effective or not
is determined by the choice and frequency of the pri-
mary outcome. Composite endpoints, that combine sev-
eral clinically related endpoints into an additive
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plines as a way of enhancing the statistical efficiency
and, thereby, reducing the costs of clinical trials. Typi-
cally, mortality is combined with other non-fatal end-
points to capture an overall assessment and achieve a
higher event rate, thus, reducing the sample size
required to show a treatment effect. For example, in car-
diology trials, non-fatal myocardial infarctions, hospitali-
zations, episodes of revascularizations, and stroke have
been combined with death in the form of a composite
e n d p o i n t .T h i sa p p r o a c ha l s oa v o i d sm u l t i p l et e s t so f
significance and its impact on type 1 errors when end-
points are tested individually.
The purpose of this paper is to propose a novel com-
posite endpoint for critical care trials, the Persistent
Organ Dysfunction (POD) combined with death. POD
builds on our understanding of multiple organ dysfunc-
tion, which is central to the pathogenesis of death and
disability in critically ill patients. Several scoring systems
have been developed to quantify the degree of organ
dysfunction during the initial phase of critical illness
[3-5]. Some preliminary work validating Sequential
Organ Failure Assessment (SOFA) score, or changes
thereof, as an early outcome measure has been pub-
lished. Vincent and colleagues showed that resolution of
SOFA scores over the first seven days is associated with
lower 28-day mortality while the development of new
organ failures during the first seven days is associated
with increased 28-day mortality [6]. However, no organ
failure scoring system has been validated as an outcome
measure at 28 days or more. Furthermore, all current
scoring systems are limited by the lack of biochemical
test results or detailed clinical variables in the latter
stages of illness, particularly when patients are dis-
charged from ICU. At 28 days, up to 52% of variables
necessary to calculate SOFA scores or organ-failure free
days are missing [6].
We define POD as the persistence of organ dysfunc-
tion requiring life-sustaining technologies and it is pre-
sent when a patient has an ongoing requirement for
vasopressors, dialysis, or mechanical ventilation at the
outcome assessments time points. Using a database
from a recent randomized trial, we evaluate the preva-
lence of POD and the validity of combining POD +
death. To validate POD, we determine whether POD is
associated with poor health outcomes at three and six
months. To demonstrate the statistical utility of POD,
we compare sample size calculations based on POD to
similar calculations using other conventional outcomes.
Materials and methods
This study is a secondary analysis of a cohort of patients
enrolled in a prospective randomized trial to evaluate
the efficacy of supplemental glutamine and antioxidant
strategies in critically ill patients (REducing Deaths due
to OXidative Stress: The REDOXS study, registered at
clinicaltrials.gov NCT00133978). The details of this trial
have been published elsewhere [7]. In brief, we enrolled
mechanically-ventilated adult patients (≥18 years old)
admitted to ICU with two or more of the following
organ failures related to their acute illness: 1. A PaO2/
FiO2 ratio of ≤300; 2. Clinical evidence of hypoperfusion
defined as the need for vasopressor agents (norepinephr-
ine, epinephrine, vasopressin, ≥5 μg/kg/minute of dopa-
mine, or ≥50 μg/minute phenylephrine) for greater than
or equal to two hours; 3. In patients without known
renal disease, renal dysfunction defined as a serum crea-
tinine ≥171 μmol/L or a urine output of less than
500 ml/last 24 hours (or 80 ml/last 4 hours if a 24-hour
period of observation not available). In patients with
acute on chronic renal failure (pre-dialysis), an absolute
increase of ≥80 μmol/L from baseline or pre-admission
creatinine or a urine output of <500 ml/last 24 hours
(or 80 ml/last 4 hours) is required; 4. A platelet count
of ≤50 × 10
9/L.
Patients were excluded from this trial if they were in
the ICU for more than 24 hours prior to enrollment,
were moribund, had a contraindication to enteral nutri-
tion, had severe acquired brain injury, had end stage
liver disease, had known seizure disorders, were preg-
nant, or were enrolled in another ICU interventional
study. Patients or their next of kin provided informed
consent prior to randomization. As per the REDOXS
study procedures, patients were randomized to receive
glutamine and antioxidant supplementation compared
to placebo. Study nutrients continued for 28 days, or
until death or discharge from the ICU. Study patients
were followed until hospital discharge or death. For sur-
viving patients, contact was made at three and six
months to document survival status and health-related
quality of life (HRQOL) using the Short Form 36 [8].
The primary outcome for this study was 28-day mortal-
ity. The secondary outcomes include duration of stay in
ICU, development of infectious complications, multiple
organ dysfunction (SOFA scores), duration of mechani-
cal ventilation, hospital length of stay, antibiotic use and
costs of care. At baseline, we collected data on patients’
admission diagnosis, severity of illness using Acute Phy-
siology and Chronic Health Evaluation (APACHE) II [9]
and SOFA scores [3], and the presence of comorbidities
using both the Charlson [10] and Functional Comorbid-
ity indices [11].
After 600 patients were enrolled, we performed an
interim analysis. Herein, we do not compare across
groups as the study is ongoing. Rather, we combined all
patients into one dataset to develop and validate POD
composite outcome measures. POD is defined as the
presence of one or more of: persistent circulatory failure
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such as norepinephrine, epinephrine, vasopressin, ≥5 μg/
kg/minute of dopamine, or ≥50 μg/minute phenylephr-
ine for more than two hours in a given day; persistent
renal failure as defined by the need for any ongoing
renal replacement therapy; or persistent respiratory/neu-
romuscular failure as defined by the ongoing need for
mechanical ventilation (not including continuous posi-
tive airway pressure or non-invasive ventilation) at the
outcome assessments time points. A patient was consid-
ered liberated from mechanical ventilation if they
remained off mechanical ventilation for more than
48 hours. Other organ systems, such as gastrointestinal,
neurological, and haematological, were not considered
as part of POD because their dysfunction is difficult to
quantify reliably in the absence of biochemical tests and
does not correlate with the use of specific life-sustaining
technologies. For the purposes of this study, we deter-
mined the presence or absence of POD at Day 28
amongst survivors. We report prevalence of POD as the
proportion of patients with the persistence of organ fail-
ure in the individual components of POD and death at
Day 28. To validate that patients with POD are different
and worse off from those without POD, we evaluated
outcomes of patients who survived to Day 28 who had
POD and those who did not. We hypothesized that
patients with POD would have a higher delta SOFA
score, longer duration of ICU stay, longer hospital stay,
higher six-month mortality, and lower three and six
month HRQOL scores compared to patients without
POD and alive at Day 28.
The Research Ethics Board at Queen’sU n i v e r s i t y
approved the REDOXS study.
Statistical Analysis
Baseline patient characteristics were compared by POD
and survival status at Day 28. Among 28-day survivors,
outcomes including Delta SOFA score (maximal SOFA-
baseline SOFA), length of stay in ICU, length of stay in
hospital, hospital mortality, post 28-day survival and
Short Form-36 scores were compared between patients
with and without POD at Day 28. Kaplan-Meier curves
with log-rank tests are used to compare post 28-day sur-
vival between these two groups. ICU and hospital length
of stay, defined as days from admission to death or dis-
charge, are described as medians with quartiles and
were tested by the Wilcoxon-Mann-Whitney test. Cate-
gorical variables are described as counts and percentages
and were tested by Fisher’sE x a c tt e s t .A l lo t h e rv a r i -
ables are described as means with standard deviations
and compared by the t-test or one-way ANOVA;
Welch’s test was used if the equality of variance
assumption was rejected by Levene’s test. All tests are
two-sided without adjustment for multiplicity, and a
P-value < 0.05 was considered statistically significant.
Analyses were completed with SAS Version 9.1 (SAS
Institution, Cary, NC, USA).
To illuminate the statistical efficiency of POD + death,
we compared the sample size requirements based on
POD + death to the traditional endpoints of 28-day
mortality, ventilator free days (VFD) [12], and organ-
failure free days (OFFD) [3] at 28 days. For all these
calculations, we use a constant power of 80% and a two-
sided alpha = 0.05. Control group event rates and
standard deviations were based on the REDOXS study
(n = 600), but the magnitude of treatment effects were
set to arbitrary but typical sizes. The sample size
requirements for the time to event endpoints were esti-
mated by the method of Freedman [13], and the other
sample size estimates were estimated by Sample Power
Version 2 (SPSS 2000, SPSS Inc., Chicago, USA) using
classic methods [14].
Results
The first 600 patients enrolled in the REDOXS study
were available for analysis for this study. At 28 days,
2.3% of patients had circulatory failure, 13.7% had renal
failure, 8.7% had respiratory failure, and 27.2% had died,
for an overall prevalence of POD + death = 46.0% (see
Table 1). Of 28-day survivors, 20.4% had only one per-
sistent organ failure, 3.0% had two and 2.5% had three.
Clinical characteristics of patients with POD, without
POD, and who died by Day 28 are shown in Table 2.
Patients without POD at Day 28 had lower baseline
Charlson Comorbidity scores, APACHE II scores, and
SOFA scores compared to survivors with POD (see
Table 2).
Of survivors at Day 28, those with POD, compared to
those without POD, had a significantly longer duration
of ICU and hospital stay, and a significantly higher hos-
pital mortality rate and delta SOFA score (see Table 3).
In addition, overall mortality from Day 28 to six months
w a sh i g h e ri np a t i e n t sa l i v ea tD a y2 8w i t hP O Dc o m -
pared to those without POD (23/113 (20.4%) deaths vs.
35/324 (10.8%), P = 0.007, see Figure 1). Finally,
patients with POD tended to have a reduced quality of
life in many of the domains of the SF-36 at three
months (see Table 4). Differences in all domains (except
‘General Health Perceptions’) were clinically important
favoring patients without PO Db u tt h e yo n l ya c h i e v e d
statistical significance for the Physical Functioning (P =
0.006) and Role Physical (P = 0.005) domains and for
the Standardized Physical Component Summary Scale
(P < 0.001). At six months, there was a trend towards
reduced Physical Function scores in patients with POD
compared to those without (P = 0.08); there were no
other differences in any domain scores between the two
groups.
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Table 5 demonstrates the sample sizes needed based on
t h ec h o i c eo ft h ep r i m a r ye ndpoint for arbitrary but
typical effect sizes. At Day 28, 27.2% of the patients
were deceased. If we assume a 25% relative risk reduc-
tion (RRR) from 27.2% in the control arm to 20.4% in
the intervention arm, then we would need 616 patients
per arm to achieve 80% power using a Chi-squared test
at a two-sided alpha = 0.05. An additional 18.8% of
patients had POD at 28 days. Since the rate of POD +
mortality is substantially higher than mortality alone, we
would require only 286 patients per arm to achieve the
same power to detect a 25% RRR from 46.0% to 34.4%.
In the current dataset, the average VFD in 28 days was
12.8 ± 10.2. With this mean and standard deviation, we
would need 161 per arm to demonstrate a 25% increase
in VFDs. The average of OFFD was 15.3 ± 11.6. We
w o u l dn e e das a m p l es i z eo f1 4 6p e ra r mt od e m o n -
s t r a t ea2 5 %i n c r e a s ei nO F F D s .T a b l e5p r o v i d e st h e
sample sizes needed for smaller, and more realistic, dif-
ferences in VFDs and OFFDs.
Discussion
We have proposed a novel composite outcome measure
for use in clinical trials of critical care interventions. We
have used a database from a randomized trial of nutri-
tion therapy to demonstrate the prevalence of persistent
organ dysfunction amongst survivors of critical illness
and to provide realistic estimates for sample size com-
parisons. We have shown that about a quarter of survi-
vors at Day 28 will still have a need for on-going
support from life sustaining technologies in an ICU
(POD). These patients who survive to Day 28 and still
have POD have a much higher subsequent mortality
rate, prolonged hospital course, and reduced quality of
life at three months compared to survivors without
POD. This is consistent with a prognostic model pro-
posed by Carson and colleagues that showed the
Table 1 Prevalence of the components of POD and death over the first 28 days
Percentage of patients
ICU day In shock On dialysis Mechanically ventilated Dead Dead or with POD*
1 84.7 6.2 96.2 0.3 98.0
2 81.2 15.0 97.3 2.0 99.7
3 55.7 19.0 89.0 5.8 96.3
4 35.8 20.7 79.5 8.5 90.8
5 24.3 20.2 70.5 10.7 84.7
6 17.3 20.5 62.5 12.0 78.8
7 14.5 20.5 53.7 13.7 73.8
8 13.5 19.8 47.0 15.5 70.0
9 13.2 19.3 41.5 16.5 65.3
10 11.0 18.8 36.5 17.7 62.7
11 9.7 18.5 31.8 18.3 58.5
12 8.8 18.7 29.2 19.0 56.8
13 6.8 18.3 26.2 20.2 55.0
14 6.0 17.5 23.2 21.2 53.0
15 5.7 16.5 20.3 22.5 50.7
16 6.0 16.0 18.5 23.5 51.0
17 5.7 15.7 17.3 24.2 50.7
18 4.3 15.0 15.7 25.0 50.0
19 3.8 14.5 15.3 25.5 50.2
20 4.2 14.2 14.2 25.8 49.7
21 3.3 13.8 13.3 26.2 48.8
22 3.2 13.8 13.0 26.3 48.8
23 2.7 13.8 12.2 26.3 48.0
24 2.3 13.8 11.5 26.7 47.8
25 1.8 13.8 11.2 26.8 47.8
26 1.8 13.8 10.0 26.8 47.0
27 2.5 13.7 9.7 26.8 46.7
28 2.3 13.7 8.7 27.2 46.0
The proportion of patients with each component of POD, death, and combined POD + death. * This column may be less than the sum of the component
columns since patients may simultaneously have more than one POD component.
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(21 days) and have persistent organ dysfunction (need
for vasopressor and haemodialysis) have a much greater
mortality than those patients with prolonged mechanical
ventilation without ongoing organ dysfunction [15].
Composite endpoints are rare in the critical care med-
icine literature; we are aware of only a few examples.
Nathens and colleagues evaluated the effect of an anti-
oxidant supplementation strategy in critically ill trauma
patients and reported the combined endpoint of ARDS
Table 2 Baseline characteristics of patients with and without pod and patients who died by Day 28
Without POD at Day 28
(n = 324)
With POD at Day 28
(n = 113)
Dead by Day 28
(n = 163)
P-value
*a
Age <0.001
bc
62.6 ± 14.4 61.8 ± 13.8 67.9 ± 13.5
Sex 0.63
Male 198 (61.1%) 70 (61.9%) 93 (57.1%)
Female 126 (38.9%) 43 (38.1%) 70 (42.9%)
Admission type <0.001
ab
Medical 233 (71.9%) 100 (88.5%) 137 (84.0%)
Surgical: Elective 42 (13.0%) 6 (5.3%) 8 (4.9%)
Surgical: Emergency 49 (15.1%) 7 (6.2%) 18 (11.0%)
Primary ICU diagnosis 0.004
a
Cardiovascular/vascular 29 (9.0%) 10 (8.8%) 19 (11.7%)
Respiratory 101 (31.2%) 32 (28.3%) 49 (30.1%)
Gastrointestinal 5 (1.5%) 2 (1.8%) 6 (3.7%)
Neurologic 3 (0.9%) 1 (0.9%) 1 (0.6%)
Sepsis 83 (25.6%) 43 (38.1%) 54 (33.1%)
Trauma 2 (0.6%) 2 (1.8%) 1 (0.6%)
Metabolic 7 (2.2%) 1 (0.9%) 4 (2.5%)
Hematologic 1 (0.3%) 2 (1.8%) 0 (0.0%)
Other 2 (0.6%) 7 (6.2%) 3 (1.8%)
Post-op: Vascular/cardiovascular 51 (15.7%) 9 (8.0%) 10 (6.1%)
Post-op: Respiratory 4 (1.2%) 0 (0.0%) 2 (1.2%)
Post-op: Gastrointestinal 21 (6.5%) 2 (1.8%) 10 (6.1%)
Post-op: Trauma 4 (1.2%) 2 (1.8%) 1 (0.6%)
Post-op: Renal 2 (0.6%) 0 (0.0%) 0 (0.0%)
Post-op: Orthopedic 1 (0.3%) 0 (0.0%) 2 (1.2%)
Post-op:Other 8 (2.5%) 0 (0.0%) 1 (0.6%)
Charleson Comorbidity Index <0.001
ab
1.2 ± 1.5 1.7 ± 2.0 1.7 ± 1.7
Functional Comorbidity Index 0.62
1.3 ± 1.4 1.2 ± 1.4 1.4 ± 1.4
APACHE II <0.001
ab
24.4 ± 6.6 28.4 ± 5.9 29.1 ± 8.0
Day 1 SOFA score <0.001
abc
7.8 ± 2.6 9.4 ± 2.8 8.7 ± 2.9
Etiology of shock 0.16
Cardiogenic 76 (23.5%) 20 (17.7%) 32 (19.6%)
Septic 203 (62.7%) 81 (71.7%) 112 (68.7%)
Neurogenic 3 (0.9%) 1 (0.9%) 0 (0.0%)
Not in shock 7 (2.2%) 4 (3.5%) 2 (1.2%)
Other 10 (3.1%) 2 (1.8%) 7 (4.3%)
Hemorrhagic 15 (4.6%) 2 (1.8%) 1 (0.6%)
Uncertain Origin 9 (2.8%) 3 (2.7%) 9 (5.5%)
* The global P-value tested against the null hypothesis that all three groups have the same mean or proportion is reported. When the global P-value < 0.05,
unadjusted pairwise comparisons were made. Significant (P < 0.05) pairwise comparisons are denoted as follows: a-survivors without POD versus survivors with
POD, b-survivors without POD versus decedents, c-survivors with POD versus decedents.
APACHE II, Acute Physiology and Chronic Health Evaluation; ICU, Intensive Care Unit; POD, Persistent Organ Dysfunction Score; SOFA, Sequential Organ Failure Assessment.
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[16]. In a randomized trial of atrial natriuretic peptide
in ischemic acute renal failure in critically ill patients,
Sward and colleagues reported on the combined event
rate of dialysis or death before or at Day 21 [17].
Schweickert et al. evaluated the impact of early physical
and occupational therapy on mechanically ventilated
patients and chose a primary endpoint of independence
with activities of daily living and ability to walk [18].
Finally, Shuster and colleagues conducted a randomized
trial of empiric fluconazole in patients at high risk of
systemic candidiasis and used a composite that consisted
of the following four variables: resolution of fever,
absence of invasive fungal infection, no discontinuation
because of toxicity, and no need for a non-study, sys-
temic antifungal medication [19]. In no case was a vali-
dation exercise, such as we have reported here,
conducted to support the use of such composites.
When POD is combined with death to form a compo-
site endpoint, the overall event rate in our dataset
increases from 27% for mortality alone to 46% for POD
or mortality with increased gains in statistical efficien-
cies that reduce the sample size required to show clini-
cally important differences compared to when 28-day
mortality is used as the primary endpoint. However, the
benefits of using POD + death as an outcome measure
are more than its impact on statistics and sample sizes.
Conceptually, POD + death provide a more comprehen-
sive evaluation of a critical care intervention, evaluating
both measures of morbidity combined with mortality.
The present reliance on 28-day mortality is not optimal
since it would suggest that a patient alive at Day 28 is
considered a ‘treatment success’ even if they are in renal
failure and bedridden requiring ongoing mechanical
ventilation. To the extent that these surviving patients
with major organ dysfunction requiring support occur
more frequently in one group in a clinical trial, this
important difference will be missed when the focus is
on mortality alone and leads to erroneous conclusions
about the efficacy of the intervention. However, the
validity of a composite measure depends on the extent
to which each individual component is similar in its
importance to individual patients [20,21]. When the
individual components are equally considered as adverse
by patients, then it may be appropriate to combine
them. However, when there is a gradient of importance
across the individual endpoints, it may be invalid to
combine them in the form of a composite. For example,
investigators evaluated the effect of corticosteroids
amongst patients with chronic obstructive pulmonary
disease and chose to combine death from any cause,
need for mechanical ventilation, and the unblinded
administration of corticosteroids together in the form of
a composite endpoint [22]. However, from a patient’s
p o i n to fv i e w ,i tc o u l db ea r g u e dt h a tas h o r tc o u r s eo f
corticosteroids would be judged to be much less of con-
cern than death or the need for mechanical ventilation,
which questions the validity of this composite. We have
shown that patients surviving at Day 28 with POD will
suffer from ongoing risk of serious morbidity, increased
mortality, and reduced quality of life at three months.
These findings support the argument that POD is simi-
lar (but not the same) in magnitude to death and it
would be appropriate to combine with death.
Because POD is associated with worse outcomes in
the future, some may argue that hospital mortality or
longer-term mortality assessments be considered as the
primary outcome to judge the efficacy of critical care
interventions [2]. We are sympathetic to this notion;
however, there are many determinants to mortality
Table 3 Association of POD with other outcomes in patients surviving to Day 28
Without POD (n = 324) With POD (n = 113) Total (n = 437) P-values
Delta SOFA score (mean ± SD) 2.1 ± 2.2 3.5 ± 3.1 2.5 ± 2.5 <0.001
Length of stay in ICU* 8.8 (6.2, 13.4) 28.0 (20.4, 43.9) 10.0 (6.7, 18.3) <0.001
Length of stay in Hospital* 22.1 (13.1, 42.0) 49.0 (30.1, 74.3) 28.3 (15.5, 53.9) <0.001
Hospital Mortality 20 (6.2%) 19 (16.8%) 39 (8.9%) 0.001
*Median (first quartile, third quartile) days from admission to discharge or death compared by the Wilcoxon-Mann-Whitney test.
ICU, Intensive Care Unit.
SOFA, Sequential Organ Failure Assessment.
POD, Persistent Organ Dysfunction Score.
Figure 1 Kaplan-Meier curve comparing time to death of
patients who were alive with and without POD at Day 28.
Patients alive at six months were censored. Differences between
curves assessed with log-rank test, P = 0.007.
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apy. For example, an 82-year-old patient was admitted
to ICU with aspiration pneumonia and respiratory fail-
ure following a stroke. Initially, the patient was in shock,
requiring vasopressors and had a transient elevation in
the serum creatinine. He was enrolled in our REDOXS
study and received 14 days of nutrient therapy (or pla-
cebo). After two weeks, the patient was liberated from
mechanical ventilation and shortly thereafter was dis-
charged from ICU where he had a prolonged stay in
hospital convalescing and rehabilitating. Two months
after his admission to ICU, he died from complications
related to his original stroke and functional disability.
This case demonstrates how an ICU therapy may be
efficacious in resolving the ICU illness and facilitating a
good recovery in the short term but the patient ulti-
mately dies at a time point very remote from his ICU
illness. If we use hospital or longer-term time frames to
judge the efficacy of our studied ICU therapies, we
increase the likelihood that these non-attributable events
may occur, resulting in so much noise that it diminishes
our effect to detect a signal (that is, the intervention
being studied has no chance at altering them) [23]. If
we use a time frame more proximate to the ICU admis-
sion and application of ICU therapy, we may have
greater sensitivity and power to detect treatment effects
compared to later outcome assessments. POD + death
at 28 days enables a comprehensive assessment of both
morbidity and mortality at a time point that will be less
likely confounded by random events unrelated to the
ICU treatment compared to hospital or longer-term out-
comes. Nevertheless, POD + death could be determined
at a longer (3 months) or shorter (14 days) time frame
Table 4 Health related quality of life scores in patients with and without POD at day 28
At 3 months Patients without POD (n = 202) Patients with POD (n = 71) P-value
PHYSICAL FUNCTIONING 50.0 ± 34.1 37.2 ± 31.5 0.006
ROLE-PHYSICAL 43.6 ± 33.0 31.1 ± 27.8 0.005
PAIN INDEX 63.9 ± 30.3 59.0 ± 31.4 0.24
GENERAL HEALTH PERCEPTIONS 53.7 ± 25.3 53.0 ± 21.8 0.84
VITALITY 47.8 ± 25.4 48.2 ± 22.8 0.92
SOCIAL FUNCTIONING 64.9 ± 32.6 62.9 ± 33.0 0.66
ROLE-EMOTIONAL 67.8 ± 31.5 69.3 ± 36.8 0.75
MENTAL HEALTH INDEX 68.9 ± 22.8 72.6 ± 19.8 0.23
STANDARDIZED PHYSICAL COMPONENT SCALE 38.2 ± 12.1 32.7 ± 10.7 <.001
STANDARDIZED MENTAL COMPONENT SCALE 46.4 ± 13.3 49.6 ± 14.1 0.09
At 6 months Patients without POD (n = 196) Patients with POD (n = 70) P-value
PHYSICAL FUNCTIONING 56.5 ± 34.7 48.1 ± 34.8 0.08
ROLE-PHYSICAL 52.8 ± 34.3 47.4 ± 31.8 0.26
PAIN INDEX 66.3 ± 30.3 65.2 ± 29.4 0.78
GENERAL HEALTH PERCEPTIONS 56.4 ± 26.5 53.3 ± 22.8 0.40
VITALITY 52.5 ± 25.5 53.0 ± 23.8 0.89
SOCIAL FUNCTIONING 71.2 ± 30.3 66.8 ± 33.4 0.31
ROLE-EMOTIONAL 74.1 ± 30.8 70.3 ± 35.0 0.39
MENTAL HEALTH INDEX 71.7 ± 22.4 74.0 ± 21.1 0.45
STANDARDIZED PHYSICAL COMPONENT SCALE 40.4 ± 13.0 38.1 ± 11.4 0.21
STANDARDIZED MENTAL COMPONENT SCALE 48.5 ± 13.3 49.4 ± 13.5 0.63
POD, Persistent Organ Dysfunction Score.
Values reported as mean ± standard deviation.
Table 5 Effect of POD+death on sample size estimates
Choice of primary outcome (effect size) Number required per
group
POD + death at 28 days (25% RRR from
46.0%)
286
28-day mortality (25% RRR from 27.2%) 616
VFD at 28-days with SD = 10.2
(1 day difference) 1,635
(2 day difference) 410
(3 day difference) 183
(4 day difference) 104
(5 day difference) 67
OFFD at 28 days with SD = 11.6
(1 day difference) 2,114
(2 day difference) 530
(3 day difference) 236
(4 day difference) 133
(5 day difference) 86
Projected sample sizes required to achieve 80% power at a two-sided alpha =
0.05 using control rates and standard deviations observed for the REDOXS
Study with arbitrary but typical effect sizes.
OFFD, organ failure free days; POD, Persistent Organ Dysfunction Score; VFD,
ventilator-free days.
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to evaluate the outcome determination may vary
depending on a number of clinical and methodological
f a c t o r s ;a n di ts h o u l db ek e p ti nm i n dt h a t ,s i n c eP O D
is time dependent, conclusions may depend on the time-
frame selected.
The validity of combining individual events together
to form a composite is also dependent on the consis-
tency of the treatment effect across events [20]. For
example, we would not want to call a treatment success-
ful if it reduced POD while increasing mortality. How-
ever, this is very unlikely since for most patients POD
would be on the pathway to death and will be present
at the time of death. Composite endpoints may also be
misleading if the number of events in the components
of greater importance is small compared to the number
of events in the components of lesser importance [21].
For example, a statement by investigators that a novel
intervention reduces a composite of death, need for dia-
lysis, and reduced serum creatinine is problematic if
most of the events were related to a rise in creatinine
and investigators found a large apparent treatment effect
on rising creatinine but not on the need for dialysis or
death. With respect to POD + death, the opposite is
found. The most important event, death, occurs much
more frequently (27%) than the rates of individual organ
failures at 28 days (2 to 14%).
Finally, for composite endpoints to be useful, we need
to demonstrate that a critical care intervention has a
consistent treatment effect across all individual compo-
nents before we can have confidence in the interpreta-
tion of the composite endpoints. The measurement of a
treatment effect can be diluted by combining endpoints,
some of which are modified by the intervention, others
which are not. For example, investigators studied the
effects of carvedilol in patients with left ventricular dys-
function following myocardial infarction [24]. The pri-
mary endpoint was the combined rates of all deaths and
cardiovascular hospital admission. The study showed
that carvedilol was associated with a significant reduc-
tion in all-cause mortality (P = 0.03) but when com-
bined with hospital admission, there was no overall
effect (P = 0.30). The mortality effect disappeared when
combined with an endpoint that did not change with
the intervention. Thus, therapeutic interventions need to
have efficacy on all the components before it will be
advantageous to combine them. For example, with the
mortality and POD rates observed so far in REDOXS,
adding POD to a mortality RRR of 25% would only
improve efficiency if the RRR of POD was at least 5%.
POD and death can ‘sensibly’ be combined as they are
aspects of the same underlying disease process, an
underlying inflammatory/immunological process that
results in acute organ failure and may result in death or
persistent organ failure. We intend to analyze and
describe the treatment effects of glutamine and antioxi-
dants on mortality and the individual components of
POD with the final results of the REDOXS study when
it is completed.
Compared to other options for outcome measures, POD
+ death offers several other advantages. In contrast to
other measures of organ dysfunction/failure which require
daily data collection, POD + death requires data collection
only on the day of assessment. Furthermore, determina-
tion of POD uses readily available clinical parameters that
will be easily discerned either prospectively or retrospec-
tively and does not suffer from large amounts of missing
data like all other organ failure scoring systems. Compared
to traditional mortality endpoints considered in this analy-
sis, POD + death requires fewer study subjects to achieve
adequate power to detect a treatment effect. Large differ-
ences in ‘failure-free days’ would require the fewest
patients. However, the advantage of POD is its simplicity,
lack of missing data, and robustness. To our knowledge,
validation exercises similar to what we have performed
with POD have not been performed for such endpoints.
Finally, by combining death with POD, we avoid the pro-
blem of maintaining type I error control over multiple
outcomes, and we eliminate the complexities involved
with analyzing and interpreting non-fatal outcomes for
which death is a competing risk.
The measurement of POD suffers limitations that are
common to other organ failure scoring systems. Ideally,
scores should be independent of clinician determined
therapeutic variables, to minimize bias in the determina-
tion of the endpoint [4]. However, this is virtually
impossible for all organ failure assessment scoring
systems. For example, PaO2/FiO2 ratios will vary
dependent on use of positive end expiratory presure,
cardiovascular scores will be influenced by use of vaso-
pressors, platelet counts are influenced by platelet trans-
fusions, and so on. For POD, all outcomes assessments
are determined by the use of life support technologies,
which are determined by clinicians. This limitation will
be less important in the context of double-blinded ran-
domized clinical trials.
Other limitations specific to POD is the lack of corre-
lation between POD and six-month quality of life assess-
ment among survivors. This is offset by the presence of
POD at 28 days being associated with mortality at six
months and may be explained by the fact that patients
with a poor outcome have either died or fully recovered
by six months.
Conclusions
Composite endpoints have their limitations. However, if
used appropriately, they can improve the statistical effi-
ciency of randomized clinical trials. We propose that
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valid outcome measure for critical care interventions
that impact on major morbidity and mortality. POD
requires a minimal investment in terms of data collec-
tion and provides a comprehensive evaluation of critical
care interventions, evaluating both morbidity and mor-
tality. If POD combined with death were used as a pri-
mary outcome for relevant critical care studies, more
trials for a given investment of research resources could
be performed, advancing our knowledge base related to
caring for the critically ill. Further validation work to
assess the relative magnitude of treatment effects across
mortality and the components of POD is warranted.
Key messages
￿ Composite endpoints, which combine several clini-
cally related endpoints into an additive outcome
measure, are commonly used in other disciplines as
a way of enhancing the statistical efficiency and,
thereby, reducing the costs of clinical trials.
￿ Approximately 20% of Day 28 survivors have per-
sistent organ dysfunction (POD) as measured by
ongoing requirement for vasopressors, dialysis, or
mechanical ventilation at 28 days.
￿ Of survivors at Day 28, those with POD, compared
to those without POD, had a higher mortality rate in
the six-month follow-up period, had longer ICU and
hospital stays, and a reduced quality of life at three
months.
￿ POD + death may be a valid composite outcome
measure and compared to mortality endpoints, may
reduce the sample size requirements of clinical trials
of critically ill patients.
￿ Further validation in larger clinical trials is required.
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